Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 06
2016
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,002
+9.05%
|
-
|
|
May 06
2016
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
746
-4.85%
|
$40,284
$54.09 P/Share
|
|
May 06
2016
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
2,001
+11.52%
|
-
|
|
May 06
2016
|
Roger M Perlmutter Exe V-P & Pres, MRL |
SELL
Payment of exercise price or tax liability
|
Direct |
26,946
-28.39%
|
$1,455,084
$54.09 P/Share
|
|
May 06
2016
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Exercise of conversion of derivative security
|
Direct |
44,464
+31.91%
|
-
|
|
May 06
2016
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,243
-4.79%
|
$67,122
$54.09 P/Share
|
|
May 06
2016
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,335
+11.4%
|
-
|
|
Apr 14
2016
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
131,040
-20.05%
|
$7,338,240
$56.11 P/Share
|
|
Apr 14
2016
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
131,040
+16.7%
|
$5,765,760
$44.19 P/Share
|
|
Apr 13
2016
|
William B Harrison Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+23.36%
|
$170,000
$34.44 P/Share
|
|
Feb 22
2016
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,537
+10.17%
|
$126,850
$50.77 P/Share
|
|
Feb 22
2016
|
Willie A Deese Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
14,557
+9.81%
|
$727,850
$50.77 P/Share
|
|
Feb 22
2016
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
11,332
+32.46%
|
$566,600
$50.77 P/Share
|
|
Feb 22
2016
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
93,241
+15.14%
|
$4,662,050
$50.77 P/Share
|
|
Feb 22
2016
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,377
+8.58%
|
$168,850
$50.77 P/Share
|
|
Feb 22
2016
|
Clark Golestani EVP & Chief Info Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,150
+25.14%
|
$307,500
$50.77 P/Share
|
|
Feb 22
2016
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Grant, award, or other acquisition
|
Direct |
16,326
+11.08%
|
$816,300
$50.77 P/Share
|
|
Feb 22
2016
|
Michael J Holston EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
11,443
+15.15%
|
$572,150
$50.77 P/Share
|
|
Feb 22
2016
|
Michael Rosenblatt Exec V-P & Chief Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,738
+15.83%
|
$386,900
$50.77 P/Share
|
|
Feb 22
2016
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
37,223
+50.0%
|
$1,861,150
$50.77 P/Share
|
|
Feb 22
2016
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
25,227
+33.43%
|
$1,261,350
$50.77 P/Share
|
|
Nov 04
2015
|
Wendell P Weeks Director |
SELL
Open market or private sale
|
Direct |
5,000
-98.04%
|
$275,000
$55.53 P/Share
|
|
Nov 04
2015
|
Wendell P Weeks Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
$170,000
$34.44 P/Share
|
|
Nov 03
2015
|
Kenneth C Frazier Executive Chair |
SELL
Bona fide gift
|
Direct |
9,000
-2.05%
|
-
|
|
Oct 29
2015
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
18,666
-4.09%
|
$1,007,964
$54.69 P/Share
|
|
Oct 29
2015
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
18,666
+3.93%
|
$653,310
$35.09 P/Share
|
|
Oct 29
2015
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
SELL
Open market or private sale
|
Direct |
37,313
-65.45%
|
$2,052,215
$55.08 P/Share
|
|
Oct 29
2015
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,313
+39.56%
|
$1,343,268
$36.56 P/Share
|
|
Oct 28
2015
|
Wendell Peter C Director |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$270,000
$54.85 P/Share
|
|
Oct 28
2015
|
Wendell Peter C Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$170,000
$34.44 P/Share
|
|
Aug 01
2015
|
Michael J Holston EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
10,168
-16.25%
|
$589,744
$58.96 P/Share
|
|
Aug 01
2015
|
Michael J Holston EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
22,584
+26.52%
|
-
|
|
Jul 31
2015
|
Clark Golestani EVP & Chief Info Officer |
SELL
Open market or private sale
|
Direct |
31,831
-18.81%
|
$1,878,029
$59.01 P/Share
|
|
Jul 31
2015
|
Clark Golestani EVP & Chief Info Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,542
+15.03%
|
$1,421,680
$40.61 P/Share
|
|
May 11
2015
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
10,634
-100.0%
|
$638,040
$60.44 P/Share
|
|
May 08
2015
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Open market or private sale
|
Direct |
38,368
-54.54%
|
$2,302,080
$60.99 P/Share
|
|
May 08
2015
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,208
+28.0%
|
$1,617,280
$35.03 P/Share
|
|
May 04
2015
|
Bruce N Kuhlik Exe V-P & Gen Counsel |
SELL
Open market or private sale
|
Direct |
56,064
-27.15%
|
$3,363,840
$60.2 P/Share
|
|
May 04
2015
|
Bruce N Kuhlik Exe V-P & Gen Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
56,064
+21.35%
|
$2,186,496
$39.29 P/Share
|
|
May 02
2015
|
Bruce N Kuhlik Exe V-P & Gen Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
6,071
-3.88%
|
$358,189
$59.86 P/Share
|
|
May 02
2015
|
Bruce N Kuhlik Exe V-P & Gen Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,708
+6.96%
|
-
|
|
May 02
2015
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,423
-6.84%
|
$83,957
$59.86 P/Share
|
|
May 02
2015
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,818
+15.51%
|
-
|
|
May 02
2015
|
Willie A Deese Exe V-P & Pres. MMD |
SELL
Payment of exercise price or tax liability
|
Direct |
3,438
-2.8%
|
$202,842
$59.86 P/Share
|
|
May 02
2015
|
Willie A Deese Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
7,636
+5.86%
|
-
|
|
May 02
2015
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Payment of exercise price or tax liability
|
Direct |
2,640
-18.13%
|
$155,760
$59.86 P/Share
|
|
May 02
2015
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
5,090
+25.9%
|
-
|
|
May 02
2015
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,214
-4.79%
|
$71,626
$59.86 P/Share
|
|
May 02
2015
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,818
+13.09%
|
-
|
|
May 02
2015
|
Clark Golestani EVP & Chief Info Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
854
-8.32%
|
$50,386
$59.86 P/Share
|